Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zura Bio

1.50
+0.10007.14%
Post-market: 1.47-0.0290-1.93%19:51 EDT
Volume:471.12K
Turnover:679.53K
Market Cap:92.81M
PE:-2.09
High:1.52
Open:1.37
Low:1.35
Close:1.40
Loading ...

Company Profile

Company Name:
Zura Bio
Exchange:
NASDAQ
Establishment Date:
2022
Employees:
30
Office Location:
1489 W. Warm Springs Road,Suite 110,Henderson,Nevada,United States
Zip Code:
89014
Fax:
- -
Introduction:
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Directors

Name
Position
Amit D. Munshi
Chairman of the Board
Robert Lisicki
Chief Executive Officer and Director
Arnout Ploos van Amstel
Independent Director
Daniel Becker
Independent Director
Jennifer Ann Jarrett
Independent Director
Neil Graham
Independent Director
Sandeep C. Kulkarni
Independent Director
Steven J. Schoch
Independent Director
Someit Sidhu
Director

Shareholders

Name
Position
Robert Lisicki
Chief Executive Officer and Director
Kimberly Ann Davis
Chief Operating Officer, Secretary and Chief Legal Officer
Eric Hyllengren
Chief Financial Officer
Gary Whale
Chief Technology Officer
Kiran Nistala
Chief Medical Officer and Head, Development